Phase 1RecruitingPriority 4 · Lower priorityNCT07055477
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Plain-language summary
This Phase 1 trial is comparing Cyclophosphamide, Fludarabine, and other medications against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years to 120 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Cyclophosphamide (DRUG): Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days | Fludarabine (DRUG): Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days | Autologous CCR4 CAR T cells (BIOLOGICAL): Day 0: Cells will be infused intravenously (IV) over 10-30 minutes
- Drugs / treatments
- Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details